Memorial Sloan Kettering Cancer Center

FDA expands Kisqali use for early-stage breast cancer, reducing recurrence risk by 25% after 3 years and 28.5% after 4 years in HR-positive, HER2-negative cases. Available for broader patient groups, it complements endocrine therapy, though costs up to $400,000 over 3 years.

FDA expands approval of Kisqali for early-stage HR-positive, HER2-negative breast cancer, reducing recurrence risk by 25% after 3 years and 28.5% after 4 years. Available to broader patient groups than Verzenio, it may cause fewer side effects and offers hope to younger women with rising breast cancer rates.

Elicio Therapeutics announces upcoming presentations on novel immunotherapies for cancer at AACR, RAS-Targeted Drug Development Summit, and Sloan Precision Oncology Institute Symposium. Presentations will cover recent Phase I trial updates and the clinical translation of RAS-targeted Amphiphile vaccines.

FDA requires mammogram facilities to inform patients about breast density, aiding cancer risk understanding and potential additional testing needs, though insurance coverage for such tests remains inconsistent.

PRT3789, a first-in-class SMARCA2 degrader, shows encouraging anti-tumor activity and tolerability in SMARCA4-mutated NSCLC and esophageal cancer patients. No dose-limiting toxicities or serious adverse events reported. Dose escalation continues, with 7/26 patients showing tumor shrinkage. Conference call scheduled for September 13, 2024.

Trastuzumab deruxtecan (T-DXd) combined with fluoropyrimidine (FP) and/or pembrolizumab showed significant antitumor activity in HER2+ esophageal, gastric, and gastroesophageal junction cancer, according to the DESTINY-Gastric03 study. Full-dose T-DXd and FP achieved the highest overall response rate (78%), while the triplet of T-DXd, FP, and pembrolizumab showed higher toxicities. A reduced-dose triplet demonstrated manageable safety. Further research is needed.

Research at WCLC 2024 highlights potential treatments for NSCLC and ES-SCLC, including ivonescimab, aumolertinib, sacituzumab govitecan, N-803, durvalumab-based combinations, amivantamab plus lazertinib, ifinatamab deruxtecan, and sacituzumab govitecan. Trials show improved PFS, OS, and ORR with these treatments.

T-DXd, with or without pembrolizumab and fluoropyrimidine, showed antitumor activity and manageable safety in HER2-positive esophageal, gastric, and GEJ cancer patients. Full-dose T-DXd and fluoropyrimidine had the highest ORR (78%), while pembrolizumab-containing arms showed higher toxicities. Reduced-dose triplets demonstrated manageable safety.

Dr. Jonathan E. Rosenberg presented 5-year follow-up results of the EV-103 Study at the 2024 ESMO Congress, showing durable responses and meaningful survival outcomes with Enfortumab Vedotin (EV) + Pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC), with a median overall survival (OS) of 26 months and 41.5% of patients alive at 5 years.